Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Elevation Oncology (ELEV)
NASDAQ:ELEV
Elevation Oncology (ELEV) Stock Price & Analysis
151 Followers
ELEV Stock Chart & Stats
Day’s Range$3.46 - $3.92
52-Week Range― - ―
Previous Close$3.88
Volume1.23M
Average Volume (3M)N/A
Market Cap
$210.17M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 02, 2024EPS Estimate
-$0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.75Price Target Upside112.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Elevation Oncology News
PremiumCompany Announcements
Lori Hu Resigns, Darcy Mootz Joins Elevation Oncology Board
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressThe HER3-ADC1 candidate has shown promising preclinical data, suggesting potential as an effective treatment for HER3-expressing tumors.
Financial OutlookWith a solid cash position and extended debt facility, Elevation Oncology expects a cash runway that would support its development activities well into the future.
Strategic Partnerships And Market ExpansionThe expansion of the EO-3021 trial to the Japanese market, a region with a high incidence of gastric cancer, may increase the potential for the candidate, coupled with the strong mechanistic rationale for its combination study.
Bears Say
Clinical RisksRisks include clinical, partnership, regulatory, and commercial challenges that could impact the company's future success.
Drug EfficacyThe efficacy of Claudin 18.2 ADCs in U.S. trials remains uncertain, with factors like different patient demographics and toxicity profiles to consider.
EarningsELEV reported a Q4 net loss of $11MM.
---
Ownership Overview
24.22% Insiders
3.18% Mutual Funds
3.42% Other Institutional Investors
69.17% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ELEV FAQ
What was Elevation Oncology’s price range in the past 12 months?
Currently, no data Available
What is Elevation Oncology’s market cap?
Currently, no data Available
When is Elevation Oncology’s upcoming earnings report date?
Elevation Oncology’s upcoming earnings report date is May 02, 2024 which is in 4 days.
How were Elevation Oncology’s earnings last quarter?
Elevation Oncology released its earnings results on Feb 29, 2024. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.232 by $0.042.
Is Elevation Oncology overvalued?
According to Wall Street analysts Elevation Oncology’s price is currently Undervalued.
Does Elevation Oncology pay dividends?
Elevation Oncology does not currently pay dividends.
What is Elevation Oncology’s EPS estimate?
Elevation Oncology’s EPS estimate is -$0.2.
How many shares outstanding does Elevation Oncology have?
Currently, no data Available
What happened to Elevation Oncology’s price movement after its last earnings report?
Elevation Oncology reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.232. Following the earnings report the stock price went up 14.545%.
Which hedge fund is a major shareholder of Elevation Oncology?
Among the largest hedge funds holding Elevation Oncology’s share is Aisling Capital Management LP. It holds Elevation Oncology’s shares valued at 2M.
---
Elevation Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.75 (112.62% Upside)
$7.75 (112.62% Upside)
Blogger Sentiment
Neutral
ELEV Sentiment 50%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.86%
12-Months-Change
Fundamentals
Return on Equity
-88.03%
Trailing 12-Months
Asset Growth
-5.38%
Trailing 12-Months
Company Description
Elevation Oncology
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
---
ELEV Stock 12 Months Forecast
Average Price Target
$7.75
▲(112.62% Upside)
Technical Analysis
Best Analysts Covering ELEV
1 Year
1 Year Success Rate
4/8 ratings generated profit
1 Year Average Return
+15.17%
assigned a buy rating 2 months ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +15.17% per trade.
---